Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy wins FDA approval for ramipril capsules
The application for the drug was submitted by Ranbaxy from the Ohm Laboratories manufacturing facility, located in North Brunswick, New Jersey, US. The office of generic drugs, FDA,
The application for the drug was submitted by Ranbaxy from the Ohm Laboratories manufacturing facility, located in North Brunswick, New Jersey, US. The office of generic drugs, FDA,
According to the company, Acanya gel is the only FDA-approved fixed combination antibiotic and benzoyl peroxide (BPO) medication for once-daily treatment of both non-inflammatory and inflammatory lesions of
Origen will use its avian transgenic technology to develop transgenic chickens, which can be immunized with any disease target of interest, including diseases such as cancer and autoimmunity.
In his previous position, Dr Lanthaler served as CFO of Intercell in Vienna, Austria, a biopharmaceutical company. In this role, Dr Lanthaler was also responsible for business development
Proceeds will be used to support future growth initiatives, including product acquisitions. As part of the transaction, Victory announced that Scott Barry, Essex Partner, has joined its board
Although preliminary data, needing further analysis, show activity of Bevasiranib when used adjunctively with Genentech’s Lucentis, review of the data by the Independent Data Monitoring Committee indicated that
Most recently, Mr Lonergan served as vice president of sales, marketing, and business development for Ibis Biosciences. Prior to Ibis, Mr Lonergan held similar executive positions at 454
According to the company, the interim results indicate that sequential treatment of plaque psoriasis with Clobex spray followed by Vectical ointment is effective in managing plaque psoriasis over
In the initial stage of the program, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed
CV Therapeutics, a biopharmaceutical company, has announced that CVT-3619, a novel oral compound for potential treatment of cardiometabolic diseases, was well tolerated with no serious adverse events and